705 results on '"Talimogene laherparepvec"'
Search Results
2. Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
3. Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
4. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
5. Neoadjuvant Combination Immunotherapy for Stage III Melanoma
6. Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT)
7. A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
8. Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
9. Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
10. Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
11. Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
12. Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
13. Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin
14. Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
15. A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
16. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report
17. Intralesional and Infusional Updates for Metastatic Melanoma.
18. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
19. Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors.
20. Neoadjuvant T-VEC in High Risk Early Melanoma
21. Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
22. Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
23. Melanoma Immunotherapy
24. Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 (MASTERKEY-318)
25. TVEC and Preop Radiation for Sarcoma (8 ml Dose)
26. Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)
27. TVEC and Preop Radiation for Sarcoma (4 ml Dose)
28. Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
29. T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
30. Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
31. Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
32. Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
33. Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)
34. Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)
35. Recent advancement in targeted therapy and role of emerging technologies to treat cancer.
36. Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
37. Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
38. Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy
39. Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma (KAPVEC)
40. Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors
41. Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
42. T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC)
43. PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
44. Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (TVEC-325)
45. Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (MASTERKEY232)
46. TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) (TITAN)
47. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
48. Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments.
49. Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).
50. A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.